NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jun 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ORAPRED ODT (prednisolone sodium phosphate) by Alcon is properties. First approved in 2006.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORAPRED ODT is an orally disintegrating tablet formulation of prednisolone sodium phosphate, a glucocorticosteroid that suppresses inflammation and immune responses. It is indicated for inflammatory and allergic conditions across multiple therapeutic areas. The drug works by inhibiting inflammatory processes, suppressing immune cell production, and modulating metabolic and endocrine functions.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; expect contraction in commercial team size and shift toward generic transition planning.
Mechanism of Action
properties. Some of these properties reproduce the physiological actions of endogenous glucocorticosteroids, but others do not necessarily reflect any of the adrenal hormones' normal functions; they are seen only after administration of large therapeutic doses of the drug. The pharmacological…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on ORAPRED ODT at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.